$0.44
0.14%Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs.
Quality against peers; 50 is the peer median.
Showing the last 4 periods. Pro adds the full annual and quarterly history and 20+ more metrics to chart.
The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.
The next report, and the record against analysts' estimates.
Fundamentals: trailing twelve months to Jun 2026, from the latest 10-K and 10-Qs.
IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.
The companies closest in size in Biotechnology (filled from its sector when there are few), with the median and rank across all 571 in the industry.